The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ApoE is strongly associated with the amount of fibrillar amyloid that deposits into plaques (28).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [28]
In the citing paper
“In addition to isoform status, it appears that the amount of apoE also plays a role in determining the extent of Aβ accumulation in the brain.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Initial studies clearly indicated that the deletion of the endogenous murine Apoe gene causes a dramatic decrease in fibrillar and total Aβ deposition in APP transgenic mouse models (Bales et al., 1997).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the lack of apoE led to a dramatic decrease of amyloid deposition in APP transgenic mouse models (Bales et al., 1997; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the absence of apoE leads to a dramatic decrease in the levels of fibrillar Aβ deposits in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Later, in vivo studies demonstrated that the lack of apoE led to a dramatic reduction of fibrillar Aβ deposition in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Reducing ApoE in mouse models of amyloidosis greatly reduces plaque formation (7, 8, 33, 34).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [33]
In the citing paper
“Both genetic deletion and pharmacological reduction of APOE reduced Aβ deposition in mouse models of AD. 3 , 4 , 5 , 6 , 7 , 8 , 9”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Notably, deletion of Apoe reduces amyloid deposition in transgenic mouse models of AD. 3 , 4”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Our findings remain consistent with the effects of apoE knock-out noted in several AD Tg mouse models, where lack of apoE was associated with absence of fibrillar Aβ deposits and prevented neurodegeneration [13,29,31,32].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [31]
In the citing paper
“Independent of apoE isoform, the amount of apoE in the brain appears to be critical for determining the extent of amyloid deposition [25,26].”
From Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) · cites this paper as [25]
In the citing paper
“ApoE gene deletion in APP transgenic mice leads to dramatically decreased amyloid plaques without affecting Aβ production (Bales et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Bales et al., 1997
In the citing paper
“The pivotal role of ApoE in brain Ab accumulation was confirmed by showing a marked reduction in Ab plaque and CAA deposits associated with the Apoe gene knockout (KO) in AD transgenic (Tg) mice.14”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Similar effects of the ApoE KO were previously reported in APP V717F and APP SW lines, representing more latent models of Ab pathology in which thioflavin-S detects the first plaques around the age of 1 year.14,55”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Reducing ApoE levels is generally protective in AD models1,4–6.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [4]
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [23]
In the citing paper
“In amyloid precursor proteineexpressing transgenic mice, deletion of mouse apoE gene inhibits development of fibrillar amyloid plaques [80,81].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [80]
In the citing paper
“ApoE strongly regulates brain amyloid-β (Aβ) deposition in a dose- and isoform-dependent manner (E4>E3>E2) (Bales et al., 1997; Holtzman et al., 2000; Schmechel et al., 1993).”
From Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms (2021) · cites this paper as Bales et al., 1997
In the citing paper
“APP transgenic mice lacking endogenous mouse apoE display a significant decrease of amyloid pathology”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“apoE-deficient APP transgenic mice display virtually no fibrillar Aβ deposits nor neuritic degeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“Initial studies using the PDAPP and Tg2576 APP transgenic mouse models that develop Aβ deposition demonstrated that the lack of murine apoE resulted in a significant decrease in Aβ deposition, along with an almost complete lack of true amyloid plaques and neuritic dystrophy (Bales et al., 1997; Holtzman et al., 2000; Holtzman et al., 1999).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Data from transgenic mouse models produced more conflicting results with impaired plaque deposition seen in mice lacking murine APOE (Bales et al., 1997; Holtzman et al., 2000), but also in animals overexpressing the human APOE3 or APOE4 isoforms (Holtzman et al., 1999).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Bales et al., 1997
In the citing paper
“Murine Apoe deletion reduced Aβ deposition in various transgenic APP mouse models (Bales, Verina et al. 1997, Bales, Verina et al. 1999, Holtzman, Fagan et al. 2000, Irizarry, Cheung et al. 2000, Ulrich, Ulland et al. 2018)”
From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Bales, Verina et al. 1997
In the citing paper
“ApoE has a major impact on the generation of amyloid deposits in the AD mouse brain and deletion of ApoE in most AD mouse models significantly inhibits amyloid plaque formation [6], [7], [8].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“APP transgenic mice deficient for ApoE show a dramatic decrease in fibrillary amyloid deposits [5], [6], [7], [8], [9].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“Total body apoE knockout as well as astrocyte specific ApoE knockout results in markedly decreased fibrillar amyloid deposition and in less compact Aβ plaques as well as decreasing neuronal loss and reactive gliosis in a tauopathy model [96, 99, 100].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [100]
In the citing paper
“In addition, the strongest genetic risk factor for LOAD, apolipoprotein E, APOE, in large part appears to increase risk via influencing Aβ seeding and clearance”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Bales et al., 1997
In the citing paper
“To date, substantial evidence has demonstrated ApoE affects amyloid-β deposition in a dosage and isoform-specific fashion (ApoE4>ApoE3>ApoE2)96–100”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [96]
In the citing paper
“Transgenic mouse studies confirmed that ApoE was necessary for the formation of fibrillar amyloid plaques and CAA [4, 5, 41, 61], however they also identified important differences between mouse and human ApoE.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [5]
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationSpontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein
Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 701
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Human apolipoprotein E: the Alzheimer's disease connection
Weisgraber, K. H., & Mahley, R. W. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.13.8940294 · Cited by 333
Hyman, B. T., West, H. L., Rebeck, G. W., Buldyrev, S. V., Mantegna, R. N., Ukleja, M., Havlin, S., & Stanley, H. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3586 · Cited by 212
Research works printed but not linked: 2
- Kim, K.S. et al. Neurosci. Res. Comm. 51, 113–122 (1990).
- Brown, B.M. & Hettmansperger, T.P. J. Am. Stat. Assoc. 91, 1668–1675 (1996).
Cited by
Sorted by citations
Items 601–700 of 829
Understanding the molecular basis of resilience to Alzheimer’s disease
Montine, K. S., Berson, E., Phongpreecha, T., Huang, Z., Aghaeepour, N., Zou, J., MacCoss, M. J., & Montine, T. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1311157 · Cited by 14
Apolipoprotein E Highly Correlates with AβPP- and Tau-Related Markers in Human Cerebrospinal Fluid
Vuletic, S., Li, G., Peskind, E. R., Kennedy, H., Marcovina, S. M., Leverenz, J. B., Petrie, E. C., Lee, V. M.-Y., Galasko, D., Schellenberg, G. D., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15307 · Cited by 12
Fadika, G. O., & Baumann, M. (2002) · Amyloid · doi:10.3109/13506120208995239 · Cited by 12
ApoE allelic variability influences pupil response to cholinergic challenge and cognitive impairment
Scinto, L. F. M. (2006) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2006.00247.x · Cited by 12
Is the ApoE polymorphism associated with dilated cardiomyopathy?
Jurkovičová, D., Gonçalvesová, E., Sedlakova, B., Hudecová, S., Fabián, J., & Križanová, O. (2006) · PubMed · Cited by 12
Seddon, A. R., MacArthur, C. P., Hampton, M. B., & Stevens, A. J. (2024) · Redox Report · doi:10.1080/13510002.2024.2428152 · Cited by 11
Juhász, A., Palotás, A., Janka, Z., Rimanóczy, Á., Palotás, M., Bódi, N., Boda, K., Zana, M., Vincze, G., & Kalman, J. L. (2005) · Neurochemical Research · doi:10.1007/s11064-005-2745-6 · Cited by 11
Srinivasan, G. R., & Brafman, D. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.813544 · Cited by 10
Apolipoprotein E receptor pathways in Alzheimer disease
Schmidt, V., Carlo, A.-S., & Willnow, T. E. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1262 · Cited by 10
The Role of APOE and NF-κB in Alzheimer’s Disease
Davies, D. A. (2021) · Immuno · doi:10.3390/immuno1040027 · Cited by 10
[44] A mouse model for serum amyloid A amyloidosis
Kindy, M. S., & de Beer, F. C. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)09046-1 · Cited by 10
Novel Susceptibility Loci for Alzheimer's DXSisease
Reitz, C. (2015) · Future Neurology · doi:10.2217/fnl.15.42 · Cited by 10
Genetic markers in the diagnosis of Alzheimer's disease
Rogaeva, E. A., Tandon, A., & George‐Hyslop, P. S. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3304 · Cited by 10
Cell cycle and chromosome segregation defects in alzheimer's disease
Potter, H., Geller, L. N., Thomas, A. E., Conforto, D., & Chichkova, R. I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83340-0 · Cited by 10
Aβ conformational change is central to Alzheimer’s disease
Holtzman, D. M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00040-4 · Cited by 10
Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease
Naidu, A., Catalano, R., Bales, K. R., Wu, S., Paul, S. M., & Cordell, B. (2001) · Neuroreport · doi:10.1097/00001756-200105080-00042 · Cited by 10
Self-citationEsler, W. P., Marshall, J. R., Stimson, E. R., Ghilardi, J. R., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (2002) · Amyloid · doi:10.3109/13506120209072439 · Cited by 10
Apolipoprotein E levels and Alzheimer risk
Hyman, B. T., & Holtzman, D. M. (2015) · Annals of Neurology · doi:10.1002/ana.24355 · Cited by 9
Strell, P., Johnson, S. T., Carchi, C., & Low, W. C. (2023) · Cell Transplantation · doi:10.1177/09636897231164712 · Cited by 10
Shukla, D., Suryavanshi, A., Bharti, S. K., Asati, V., & Mahapatra, D. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266299847240328045737 · Cited by 10
Posttranslational modification of lipoproteins – A fatal attraction in metabolic disease?
Bierhaus, A., & Nawroth, P. P. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7407 · Cited by 9
Kagita, S., Uppalapati, S., Gundeti, S., & Digumarti, R. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv064 · Cited by 9
Calabrò, P., & Yeh, E. T. H. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0114-6 · Cited by 9
Is Apolipoprotein E Required for Cognitive Function in Humans?
Lane‐Donovan, C., & Herz, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2013 · Cited by 8
Three‐dimensional view of microglia—amyloid plaque interactions
Gotkiewicz, M., Capra, J., Miettinen, P. O., Natunen, T., & Tanila, H. (2024) · Glia · doi:10.1002/glia.24628 · Cited by 11
LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice
Stukas, S., Freeman, L., Lee, M., Wilkinson, A., Ossoli, A., Vaisman, B., Demosky, S., Chan, J., Hirsch-Reinshagen, V., Remaley, A. T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049940 · Cited by 9
Ahuja, M., Patel, M., Majrashi, M., Mulabagal, V., & Dhanasekaran, M. (2017) · Medicinal and aromatic plants of the world · doi:10.1007/978-981-10-5978-0_1 · Cited by 9
Ganor, R. S., Harats, D., Schiby, G., Rosenblatt, K., Lubitz, I., Shaish, A., & Salomon, O. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8127 · Cited by 8
Morishima‐Kawashima, M., Han, X., Tanimura, Y., Hamanaka, H., Kobayashi, M., Sakurai, T., Yokoyama, M., Wada, K., Nukina, N., Fujita, S. C., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04400.x · Cited by 8
Grenon, M. B., Papavergi, M.-T., Bathini, P., Sadowski, M. J., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115754 · Cited by 7
A common 19 bp APOE enhancer deletion is protective against Alzheimer’s disease in African Americans
Brutman, J. N., Busald, T., Nizamis, E., Kaufman, E. J., Lin, E., Hendricks, N. E., Chintamen, S., Sulovari, A., Smukowski, S. N., Ye, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68808-3 · Cited by 7
Zhang, X., Gao, R., Yang, L., Zhu, Y., Zhang, T., Shen, X., Gu, W., Yang, L., & Peng, S. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.287 · Cited by 8
The Impact of the Apolipoprotein E Genotype on Cardiovascular Disease and Cognitive Disorders
McMaster, M. W., Shah, A., Kangarlu, J., Cheikhali, R., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000703 · Cited by 9
Si, X., Li, Y., Jiang, Y., Shang, W., Shui, G., Lam, S. M., BLANCHARD, C. L., Strappe, P., & Zhou, Z. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b05246 · Cited by 7
New APOE-related therapeutic options for Alzheimer’s disease
Li, Z. (2019) · AIP conference proceedings · doi:10.1063/1.5085515 · Cited by 8
Apolipoprotein E loss of function: Influence on murine brain markers of physiology and pathology
Buchanan, H. M., Hull, C. E., Barraza, M. C., Delibegović, M., & Platt, B. (2022) · Aging Brain · doi:10.1016/j.nbas.2022.100055 · Cited by 7
Mazzucca, C. B., Cappellano, G., & Chiocchetti, A. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230502123255 · Cited by 7
Frisardi, V. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111568 · Cited by 7
Polymorphism of Apolipoproteine E in Relation with Alzheimer and Vascular Dementia
Gdovinová, Z., Habalová, V., & Novosadová, Z. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9043-y · Cited by 7
Janciauskiene, S. M., Sun, Y., & Wright, H. T. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0519 · Cited by 7
The emerging utility of animal models of chronic neurodegenerative diseases
Kahle, P. J., & Haass, C. (2001) · Emerging Therapeutic Targets · doi:10.1517/14728222.5.1.125 · Cited by 7
Mechanism of Neuronal Death in Alzheimer’s Disease
Irizarry, M. C. (2002) · Advances in behavioral biology · doi:10.1007/978-0-306-47593-1_23 · Cited by 7
β‐Amyloid Therapeutic Strategies for Alzheimer's Disease
Imbimbo, B. P., & Speroni, F. (2005) · Wiley eBooks · doi:10.1002/0471266949.bmc112 · Cited by 6
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 8
Azmi, N. H., Ismail, N., Imam, M. U., Ooi, D. J., Zhang, Y., Aziz, A. H. A., & Rosdi, M. N. M. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105587 · Cited by 5
Lelos, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00002-7 · Cited by 5
Discrepancies between Apolipoprotein E Phenotyping and Genotyping in the Elderly
Dupuy, A., Badiou, S., Ritchie, K. A., Mas, E., Descomps, B., Cristol, J., & Touchon, J. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.065 · Cited by 6
Acetylcholinesterase inhibitors and nanoparticles on Alzheimer’s disease: a review
Silva, S., Almeida, A. J., & Vale, N. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-05118-9 · Cited by 6
New Light on a Long‐Known Protein Family
Andersen, O. M., & Petersen, H. H. (2003) · ChemBioChem · doi:10.1002/cbic.200300580 · Cited by 6
Animal models of Alzheimer's disease
Higgins, L. S. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01465-3 · Cited by 6
Cell Cycle and Chromosome Segregation Defects in Alzheimer’s Disease
Potter, H. (2005) · Springer eBooks · doi:10.1007/0-387-29390-6_5 · Cited by 6
Manni, M. E., Cescato, R., & Paganetti, P. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00469-4 · Cited by 6
Ciurleo, G. C. V., Tavares-Júnior, J. W. L., Vieira, C. M. A. G., Braga‐Neto, P., & Oriá, R. B. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1229073 · Cited by 5
Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer’s disease
Marian, O. C., Tran, C., & Don, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00023-3 · Cited by 5
Homocysteine: A Possible Modifiable Risk Factor in Vascular Dementia
Pandey, P., & Pradhan, S. (2006) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.2006.130103 · Cited by 5
Apolipoprotein E4 inhibits γ‐secretase activity via binding to the γ‐secretase complex
Sun, Y., Islam, S., Gao, Y., Nakamura, T., Zou, K., & Michikawa, M. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15750 · Cited by 5
Harasta, A. E., & Ittner, L. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_1 · Cited by 5
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer’s Disease
Oldham, C. E., & Lopez, D. (2018) · International Journal of Biomedical Investigation · doi:10.31531/2581-4745.1000106 · Cited by 5
Folkesson, R., Winblad, B. G., & Benedikz, E. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200207000-00015 · Cited by 5
Estelami, N., Khalaj‐Kondori, M., & SheikhzadehHesari, A. (2016) · Journal of Physiology and Pharmacology Advances · doi:10.5455/jppa.20160211060059 · Cited by 5
Abedini, A., & Raleigh, D. P. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch23 · Cited by 5
Holtzman, D. M. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307000-00006 · Cited by 5
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
Inhibition of Sirt2 Decreases ApoE Secretion in Astrocytes and Microglial Cells
Chen, Y., Zhou, C., Abdelhamid, M., Jung, C., & Michikawa, M. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad054 · Cited by 4
Transgenic Animal Models of Neurodegenerative Diseases
Chan, A. W. S., & Ağca, Y. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-285-4_35 · Cited by 5
The Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
Serrano, E., Sanz, P. G., & Barrantes, F. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_29 · Cited by 4
The Aβcentric Pathway of Alzheimer’s Disease
Villemagne, V. L., Cappai, R., Barnham, K. J., Cherny, R. A., Opazo, C., Novakovic, K. E., Rowe, C. C., & Masters, C. L. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_2 · Cited by 4
Aktueller Stand der Immuntherapie bei Alzheimer-Krankheit
Grimmer, T., Perneczky, R., & Kurz, A. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2491-5 · Cited by 4
Church baptizes Joseph and Perry. Eccentric views absolved
Cole, G. M. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00214-1 · Cited by 4
The APOE-491 A/T promoter polymorphism effect on cognitive profile of Alzheimer's patients
Valenza, A., Bizzarro, A., Marra, C., Lauria, A., Guglielmi, V., Rossi, C., Tiziano, F. D., Brahe, C., & Masullo, C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.004 · Cited by 4
Disease models: relevance is everything
Brooksbank, C. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01495-1 · Cited by 4
Molecular Aspects of Memory Dysfunction in Alzheimer’s Disease
Chin, J., Roberson, E. D., & Mucke, L. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00015-2 · Cited by 5
Alzheimer’s Disease and Other Neurodegenerative Disorders
Li, L., & Lewis, T. L. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-385-5_25 · Cited by 5
Amyloid-Aggregate, Präseniline und die Alzheimer-Krankheit
Baumeister, R., & Eimer, S. (1998) · Angewandte Chemie · doi:10.1002/(sici)1521-3757(19981102)110:21 · Cited by 4
New familial forms of cerebral amyloid and dementia
Vidal, R., Ghiso, J. A., & Frangione, B. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000797 · Cited by 4
Animal Models of Alzheimer’s Disease
Koenigsknecht-Talboo, J., & Holtzman, D. M. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00483-6 · Cited by 4
Borchelt, D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120414 · Cited by 3
Peripheral Markers of Alzheimer’s
Percy, M. E., Andrews, D. F., & Potter, H. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_9 · Cited by 3
Les formes tardivesde la maladie d’Alzheimer : de la génétique à la biologie
Chartier‐Harlin, M., Goumidi, L., & Lambert, J. (2002) · médecine/sciences · doi:10.1051/medsci/20021867709 · Cited by 5
Robert, J., Cheng, W. H., Hayat, A., Ward-Able, T., & Wellington, C. L. (2015) · Clinical Lipidology · doi:10.2217/clp.14.64 · Cited by 3
Apolipoproteína E e Doença de Alzheimer
Prado, D., & Cardoso, I. L. (2013) · Revista Neurociências · doi:10.4181/rnc.2013.21.775.8p · Cited by 3
Rogaeva, E. A., Meng, Y., Lee, J. H., Mayeux, R. P., Farrer, L. A., & George‐Hyslop, P. S. (2009) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-540-87941-1_12 · Cited by 3
Akatsu, H., Kamino, K., Yamagata, H. D., Isojima, D., Kondo, I., Yamamoto, T., Kida, T., Takeda, M., Miki, T., & Kosaka, K. (2004) · Psychogeriatrics · doi:10.1111/j.1479-8301.2004.00058.x · Cited by 4
Apolipoproteins in Different Amyloidoses
Sadowski, M., & Wısnıewskı, T. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_6 · Cited by 3
Mayeux, R. P., & Gandy, S. (2000) · Elsevier eBooks · doi:10.1016/b978-012288145-9/50112-1 · Cited by 3
Search for reliable diagnostic markers for Alzheimer's disease
Andreasen, N. (2000) · Figshare · Cited by 3
Feng, B., Freitas, A. E., Tian, R., Lee, Y. R., Grewal, A. S., Wang, J., & Zou, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.273011 · Cited by 3
Ferguson, C. M., Hildebrand, S. R., Godinho, B. M. D. C., Buchwald, J. E., Echeverria, D., Coles, A. H., Grigorenko, A. P., Vanjielli, L., Sousa, J., McHugh, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.28.498012 · Cited by 3
Genetic Testing in the Early Diagnosis of Alzheimer’s Disease
Blacker, D., & Tanzi, R. E. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_5 · Cited by 3
Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors
Karahan, H., Hartigan, K., Al‐Amin, M. M., John, S. K., McCord, B., Wijeratne, H. R. S., Acri, D. J., Smith, D. C., Dabin, L. C., Cordero, H. M. R., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70949 · Cited by 2
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Self-citationComparison of the ApoE allelic variants in the formation of intracerebral Aβ deposits
Xu, G. M., Angelle, C., Huilgol, D., Sacilotto, P., McFarland, K. N., Fromholt, S., Lopez, A., Vo, Q., Rivasplata, A., Brkic, S., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107105 · Cited by 2
Novel APOE Mutation in a Moroccan Subject Suffering from Alzheimer Disease
Razouqi, Y., Bouchikhi, I. E., El‐Abid, H., Baammi, S., Nedbour, A., Ahami, A. O. T., Allali, A. E., & Bouguenouch, L. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000590 · Cited by 2
Linking Cerebral Malaria Pathogenesis to APOE-Mediated Amyloidosis: Observations and Hypothesis
Mwikali, K., Mwangi, S., Njunge, J. M., Berkley, J. A., Bejon, P., & Abdi, A. I. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04366-3 · Cited by 4
Treatment of Alzheimer's disease
Sano, M. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.033 · Cited by 2
Alzheimer's Disease: Approaches to Pathogenesis in the Genomic Age
Sutherland, G. T., & Jillian, J. (2012) · InTech eBooks · doi:10.5772/36505 · Cited by 2
Biological Transgenic Mouse Models of Alzheimer's Disease
Crews, L. A., Rockenstein, E. M., & Masliah, E. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01227-4 · Cited by 2
Beneficial Effects of Statins on Experimental Amnesia
Prakash, A. K., Singh, N., & Singh, M. (2007) · Iranian journal of pharmacology & therapeutics · Cited by 2
Genes associated with Alzheimer Disease
Munshi, A., & Ahuja, Y. R. (2010) · Cited by 2
Designing Animal Models of Alzheimer's Disease with Amyloid Precursor Protein (APP) Transgenes
Loring, J. F. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:249 · Cited by 2
Metadata
- Authors
- Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., Piccardo, P., Ghetti, B., & Paul, S. M.
- Affiliations
- Eli Lilly (United States) (US)
- Indiana University School of Medicine (US)
- Philipps University of Marburg (DE)
- Venue
- Nature Genetics
- Published
- 1997-11
- Volume
- 17
- Issue
- 3
- Pages
- 263-264
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1981554609
- Cited by
- 830
- References
- 14
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 27 · 2023: 18 · 2022: 25 · 2021: 19 · 2020: 27 · 2019: 24 · 2018: 16 · 2017: 21 · 2016: 20 · 2015: 19 · 2014: 21 · 2013: 16 · 2012: 20
- FWCI
- 26.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, amyloid-beta, amyloid deposition, Alzheimer's disease, APOE genotype, apolipoprotein E deficiency
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Apolipoproteins E, Brain, Humans, Immunohistochemistry, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, RNA, Messenger, Polymerase Chain Reaction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
